Trial · NCT06678074
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
NCT06678074, Phase 1, Phase 2, Active not recruiting, Implicit Bioscience
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI. Trials, record NCT06678074. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06678074
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
- NCT number
- NCT06678074
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Implicit Bioscience
- Conditions
- STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
- Interventions
- Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once
- First posted
- 2024-11-07
- Last updated
- 2026-03-27
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (safety and tolerability) | Day 1-29 | Treatment-emergent adverse events |
| Secondary | CCR2+ cell myocardial infiltration (optional) | 48 hours and Day 15 | Characterization of CCR2+ cell myocardial infiltration mean standard uptake value (SUVmean) and change from 48 hours measured by myocardial PET/CT imaging at Day 15 |
| Secondary | Biomarker C-Reactive Protein | Day 4, 15, 29 | Change from baseline |
| Secondary | Biomarker White Blood Cell Count | Day 4, 15, and 29 | Change from baseline |
| Secondary | Biomarker Fibrinogen | Day 4, 15, 29 | Change from baseline |
| Secondary | Biomarker Interleukin 6 | Day 4, 15, and 29 | Change from baseline |
| Secondary | Biomarker Interleukin-1 | Day 4, 15, and 29 | change from baseline |
| Secondary | Biomarker Troponin I | Day 4, 15, and 29 | change from baseline |
| Secondary | Single-cell RNASeq | Day 4, 15, and 29 | change from baseline |
| Secondary | Cardiac death or readmission for heart failure | Day 1-90 | * Cardiac death defined as death due to acute MI, sudden cardiac death, HF, stroke, cardiovascular procedure, cardiovascular hemorrhage, or other cardiovascular cause. * Heart failure readmission, defined as an event in which the patient is admitted to the hospital with a primary diagnosis of HF, the length of stay is at least 24 hours (or extends over a calendar date), the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06678074
GET https://conductscience.org/api/trials/v1/NCT06678074/registered